4th Swedish Medicinal Chemistry Symposium

The organisers invite you to participate in the 4th Swedish Medicinal Chemistry Symposium, Sweden’s premier biennial Medicinal Chemistry and Drug Discovery event focusing on recent advances in Swedish drug discovery research in academia and in industry.

The 2024 symposium has a particular focus on novel concepts used in medicinal chemistry and chemical biology, including case stories highlighting recent progress.

At the Symposium, the Swedish Pharmaceutical Society 2024 Medicinal Chemistry prize-winner will be announced. The prize recognizes outstanding contributions to the areas of Medicinal Chemistry and Drug Discovery in Sweden.

Welcome to join us in Stockholm in April!

Confirmed speakers

Application of SYN321 in Osteoarthritis Management. The Science behind the Local Injection Technology HYDRO-LINK
Antonio Bermejo Gómez, Synartro

Development and Mechanism of the MTHFD1/2 Inhibitor TH9619
Martin Henriksson, One-Carbon Therapeutics

An IL-17A crystallization system supporting small molecule structure-based drug design
Maria Håkansson, Saromics

Is functionalization of C-H bonds interesting in medicinal chemistry?
Magnus Johansson, AstraZeneca

The FragMAX facility for structure-based drug discovery at MAX IV Laboratory
Tobias Krojer, MAX IV Laboratory

Targeting metabolic reprogramming in leukemia
Karin Lindqvist, Lund University

Discovery and pre-clinical characterization of AZD4604, a potent and selective inhaled JAK1 inhibitor in clinical development
Magnus Nilsson, AstraZeneca

In vivo assembly of bioresorbable organic bioelectronics as a therapeutic modality
Roger Olsson, Lund University

Accelerating drug design with AI & simulation
Jon Paul, AstraZeneca

Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells
Stefan Svensson Gelius, Oncopeptides

Program to be announced.

Call for posters and short presentations

Contributions from the whole field of medicinal chemistry and chemical biology are invited. Poster presenters will be asked to provide a two-minute presentation of highlighting findings presented in the poster. We are also inviting proposals for short presentations of recent “hot from the lab data”.

Poster abstract submissions should be sent to info@lakemedelsakademin.se by the closing date of March 11. 

Abstract instructions
Poster instructions

Sponsor possibilities

Gold sponsor
Fee: SEK 40.000 excl VAT

Benefits
• Exhibition stand with space for one roll-up
• 1 free registration

Exposure
• Special thanks in the opening speech
• Acknowledgement and website link with logo on symposium website
• Acknowledgement in final program

Silver sponsor
Fee: SEK 20.000 excl VAT

Exposure
• Special thanks in the opening speech
• Acknowledgement and website link with logo on symposium website
• Acknowledgement in final program

For questions and registration please send an email to jeanette.jansson@lakemedelsakademin.se

Who should attend?

This conference targets academic and industrial scientists engaged in all aspects of drug discovery and drug development. It aims to showcase the most recent trends in Drug Discovery presented by leading Swedish scientists. The meeting provides an excellent forum for networking with colleagues active in the field.

Participation fee and scholarship opportunities

Registration fee
Academy 3000 SEK
Industry 4700 SEK

There is an excellent opportunity for PhD students and  PhD degree holders to get travel costs and registration fee covered by  Apotekarsocieteten scholarship. A separate announcement will be made for this symposium on February 1. More information here.

From March 11 additional SEK 1000 will be added to the fee.

All prices are excl. VAT

Casual dinner (optional)
Casual dinner on April 17, 450 SEK excluding VAT. The dinner takes place in the restaurant at Westmanska.
If you want to participate, please add it on your registration.

Organizing Committee

Dr. Katarina Färnegårdh, Oncopeptides
Prof. Anna Linusson, Umeå University
Prof. Ulf Nilsson, Lund University
Dr. Lena Ripa, AstraZeneca
Dr. Peter Sjö, Drugs for Neglected Diseases initiative (DNDi), The Section for Medicinal Chemistry at Apotekarsocieteten